Learn More
BACKGROUND Colony-stimulating factors (CSFs) significantly decrease the risk of febrile neutropenia (FN), a common complication of myelosuppressive chemotherapy. Pegfilgrastim (6 mg), introduced in(More)
ObjectiveThe present study established the psychometric properties of the Functional Assessment of Cancer Therapy–Neutropenia (FACT-N), a self-report instrument to assess neutropenia-specific(More)
BACKGROUND Most alterations to chemotherapy dose and schedule are because of neutropenic events, which mainly occur in the first chemotherapy cycle. This prospective, community-based study evaluated(More)
8569 Background: Neutropenia is the major dose-limiting complication of myelosuppressive chemotherapy (CT). The Awareness of Neutropenia in CT (ANC) Study Group has prospectively documented cycle 1(More)